Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* RAVICH MARK H	2. Issuer Name and Ticker or Trading Symbol ROCKWELL MEDICAL, INC. [ RMTI ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O ROCKWELL MEDICAL, INC., 411 HACKENSACK AVENUE, SUITE 501	3. Date of Earliest Transaction (MM/DD/YYYY) 9/3/2020
(Street) HACKENSACK, NJ 07601 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	9/3/2020		J⁽¹⁾		173905	D	$1.21 ⁽²⁾	213604 ⁽³⁾	D
Common Stock	9/3/2020		J⁽¹⁾		11000 ⁽⁴⁾	D	$1.21	0	I	By: Norman and Sally Ravich Family Trust ⁽⁵⁾
Common Stock	9/3/2020		J⁽¹⁾		194905	A	$1.22 ⁽⁶⁾	194905	I	By: Cindy Libman Irrevocable Trust ⁽⁷⁾
Common Stock	9/4/2020		J⁽¹⁾		10000	D	$1.16	203604 ⁽³⁾	D
Common Stock	9/4/2020		J⁽¹⁾		16000	D	$1.16	9000	I	By: Alexander Coleman Ravich 1991 Irrevocable Trust ⁽⁸⁾
Common Stock	9/4/2020		J⁽¹⁾		9000	D	$1.16	16000	I	By: Alyssa Danielle Ravich 1991 Irrevocable Trust ⁽⁹⁾
Common Stock	9/4/2020		J⁽¹⁾		25000	A	$1.22 ⁽¹⁰⁾	219905	I	By: Cindy Libman Irrevocable Trust ⁽⁷⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:
(1)	Represents the transfer of shares of common stock to Cindy Libman Irrevocable Trust ("CL Trust") for which the Reporting Person is the trustee. The Reporting Person's total beneficial ownership in the Issuer has not changed, as he was the beneficial owner of these shares both before and after the transfers reported herein.
(2)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range.
(3)	Includes 30,000 shares of common stock underlying unvested restricted stock units that vest based on the achievement of certain time-based milestones.
(4)	Includes 1,000 shares which were inadvertently omitted in previous filings due to administrative error.
(5)	Represents securities owned directly by Norman and Sally Ravich Family Trust ("NSR Trust"). Mr. Ravich, as the trustee of NSR Trust, may be deemed to beneficially own the securities owned directly by NSR Trust.
(6)	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.23 inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range.
(7)	Represents securities owned directly by CL Trust. Mr. Ravich, as the trustee of CL Trust, may be deemed to beneficially own the securities owned directly by CL Trust.
(8)	Represents securities owned directly by Alexander Coleman Ravich 1991 Irrevocable Trust ("ACR Trust"). Mr. Ravich, as the trustee of ACR Trust, may be deemed to beneficially own the securities owned directly by ACR Trust.
(9)	Represents securities owned directly by Alyssa Danielle Ravich 1991 Irrevocable Trust ("ADR Trust"). Mr. Ravich, as the trustee of ADR Trust, may be deemed to beneficially own the securities owned directly by ADR Trust.
(10)	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.21 to $1.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
RAVICH MARK H C/O ROCKWELL MEDICAL, INC. 411 HACKENSACK AVENUE, SUITE 501 HACKENSACK, NJ 07601	X